AMR SVG Icons location

One company, limitless capabilities.

American Regent’s acquisition of HBT Labs supports our growing product portfolio and an exciting expansion into the oncology market. HBT Labs significantly increases American Regent’s capabilities in the production of complex, highly specialized drugs and delivery systems, aligning with our mission to speed distribution of high-quality medicines to the providers and patients who need them.

How the merger strengthens our products, growth, and future:

A key American Regent strategy is the development and delivery of complex, hard-to-manufacture injectables that other companies don’t provide. In merging with HBT Labs, a company that has excelled in this niche for a decade, we are well positioned to pursue this strategy to differentiate ourselves in the market.

Our focus is high-barrier, parenteral generic drugs with complex chemistry and manufacturing processes. This pipeline of drugs includes generic and 505(b)(2) products that target various treatment indications including cancer and CNS disorders. American Regent will support the launch of HBT’s new drug application for the use of Paclitaxel, a chemotherapy medicine.

The merger adds a 50,000-square-foot manufacturing facility in Brea, CA to our Ohio and New York facilities, expanding our base for continued innovation. As drugs become more complex and patient delivery systems more specific, fewer companies have the capacity to create solutions. The specialized staff, equipment, and facilities in Brea, CA will expand American Regent’s ability to manage end-to-end development of technically challenging drugs and a platform for continued innovation, clinical trials, out-licensing, or simply solving technical issues and commercializing their products. It also gives us a well-rounded portfolio of products and a platform for continued innovation.

The merger aligns with American Regent’s investment in expanding our US-based manufacturing, extending our geographic footprint to the West Coast. As one team, we’ll continue groundbreaking pharmaceutical work, providing more patients and providers with more innovative medicines and compelling solutions.